Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) will likely be releasing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Xenon Pharmaceuticals to post earnings of ($1.17) per share and revenue of $1.3640 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the company posted ($0.84) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock traded up $1.20 during trading hours on Monday, hitting $57.33. 292,834 shares of the company’s stock were exchanged, compared to its average volume of 1,286,312. The stock’s 50-day moving average is $53.79 and its 200-day moving average is $46.29. The stock has a market cap of $5.54 billion, a price-to-earnings ratio of -13.17 and a beta of 0.65. Xenon Pharmaceuticals has a 52 week low of $28.19 and a 52 week high of $63.95.

Insider Activity

In other news, insider Christopher John Kenney sold 2,771 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the transaction, the insider owned 4,729 shares of the company’s stock, valued at $284,260.19. This represents a 36.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $361,980. This trade represents a 97.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 296,707 shares of company stock valued at $17,845,365 over the last 90 days. 4.07% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several large investors have recently made changes to their positions in XENE. Goldman Sachs Group Inc. lifted its stake in shares of Xenon Pharmaceuticals by 7.9% during the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after acquiring an additional 32,486 shares during the period. Jump Financial LLC acquired a new position in Xenon Pharmaceuticals in the second quarter valued at about $532,000. Sei Investments Co. acquired a new position in Xenon Pharmaceuticals in the second quarter valued at about $711,000. The Manufacturers Life Insurance Company acquired a new position in Xenon Pharmaceuticals in the second quarter valued at about $816,000. Finally, Alliancebernstein L.P. lifted its stake in Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after buying an additional 189,141 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on XENE. Wolfe Research began coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a report on Monday, March 9th. Robert W. Baird increased their target price on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Wells Fargo & Company increased their target price on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, March 10th. Finally, Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $73.13.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.